Anti-Cea Car-T Cells
Carcinoma
China Medical University, ChinaCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin AstraZeneca | Phase 4 | BB |
Docetaxel Merck Sharp & Dohme LLC | Phase 3 | BB |
Osimertinib AstraZeneca | Phase 3 | BB |
Crizotinib Ariad Pharmaceuticals | Phase 3 | BB |
ALBUMIN AGGREGATED Sirtex Medical | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Anti-Cea Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →